Search a title or topic

Over 20 million podcasts, powered by 

Player FM logo
Artwork

Content provided by Back Bay Life Science Advisors, Jonathan P. Gertler, and Peter Bak. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Back Bay Life Science Advisors, Jonathan P. Gertler, and Peter Bak or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
Player FM - Podcast App
Go offline with the Player FM app!

From NASH to MASH: Current Market Dynamics in Hepatology

28:19
 
Share
 

Manage episode 440268113 series 2991382
Content provided by Back Bay Life Science Advisors, Jonathan P. Gertler, and Peter Bak. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Back Bay Life Science Advisors, Jonathan P. Gertler, and Peter Bak or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.

After a summer away from podcasting, Back Bay Life Science Advisors’ Dr. Pete Bak and Christian Thienel are back on the mic to discuss current market dynamics in liver disease with a focus on one of the most closely watched space in hepatology, MASH.

The big news includes a rebrand from NASH (non-alcohol related steatohepatitis) to MASH (metabolic dysfunction-associated steatohepatitis), the FDA approval of Madrigal Pharmaceutical’s Rezdiffra and real-time court rulings in Europe that may affect the rate of play for Ocaliva, a drug used to treat adults with primary biliary cholangitis here in the US. As Christian mentions in this episode, “The path to success is not always a straight line.”

Other topics in this podcast include:

  • Hepatology market dynamics over the past five years, including activity from Gilead, Novo Nordisk, Intercept and CymaBay
  • How treatment for primary biliary cholangitis, an autoimmune condition, went from a one to a three-product market
  • Payer monographs and what’s required for hepatology drugs
  • The EMA recommendation earlier this month to revoke Ocaliva’s marketing authorization
  • Which companies are active in the rare liver disease space and how they differentiate themselves

Thank you for listening. You can find previous episodes of the podcast here.

We’d love to hear from you. Ask questions and submit your feedback.

  continue reading

32 episodes

Artwork
iconShare
 
Manage episode 440268113 series 2991382
Content provided by Back Bay Life Science Advisors, Jonathan P. Gertler, and Peter Bak. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Back Bay Life Science Advisors, Jonathan P. Gertler, and Peter Bak or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.

After a summer away from podcasting, Back Bay Life Science Advisors’ Dr. Pete Bak and Christian Thienel are back on the mic to discuss current market dynamics in liver disease with a focus on one of the most closely watched space in hepatology, MASH.

The big news includes a rebrand from NASH (non-alcohol related steatohepatitis) to MASH (metabolic dysfunction-associated steatohepatitis), the FDA approval of Madrigal Pharmaceutical’s Rezdiffra and real-time court rulings in Europe that may affect the rate of play for Ocaliva, a drug used to treat adults with primary biliary cholangitis here in the US. As Christian mentions in this episode, “The path to success is not always a straight line.”

Other topics in this podcast include:

  • Hepatology market dynamics over the past five years, including activity from Gilead, Novo Nordisk, Intercept and CymaBay
  • How treatment for primary biliary cholangitis, an autoimmune condition, went from a one to a three-product market
  • Payer monographs and what’s required for hepatology drugs
  • The EMA recommendation earlier this month to revoke Ocaliva’s marketing authorization
  • Which companies are active in the rare liver disease space and how they differentiate themselves

Thank you for listening. You can find previous episodes of the podcast here.

We’d love to hear from you. Ask questions and submit your feedback.

  continue reading

32 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Listen to this show while you explore
Play